# A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy

> **NCT02006706** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 15 (actual)

## Conditions studied

- Rheumatoid Arthritis

## Interventions

- **DRUG:** rituximab [MabThera/Rituxan]
- **DRUG:** methotrexate
- **DRUG:** methylprednisolone

## Key facts

- **NCT ID:** NCT02006706
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08-10
- **Primary completion:** 2007-11-23
- **Final completion:** 2007-11-23
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2017-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02006706

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02006706, "A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD Therapy". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT02006706. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*